Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos-induced malignancy. New and effective strategies for diagnosis, prognostication, and treatment are urgently needed. Herein we review the advances in MPM achieved in 2017. Whereas recent
epidemiological data demonstrated that the incidence of MPM-related death continued to increase in United States between 2009 and 2015, new insight into the molecular pathogenesis and the immunological tumor microenvironment of MPM, for example, regarding the role of BRCA1 associated protein 1 and the expression programmed death receptor ligand 1, are highlighting new potential therapeutic strategies. Furthermore, there continues to be an ever-expanding number of clinical studies investigating systemic therapies for MPM. These trials are primarily focused on immunotherapy using immune checkpoint inhibitors alone or in combination with other immunotherapies and nonimmunotherapies. In addition, other promising targeted therapies, including pegylated adenosine deiminase (ADI-PEG20), which focuses on argininosuccinate synthase 1-deficient tumors, and tazemetostat, an enhancer of zeste 2 polycomb repressive complex 2 subunit inhibitor of BRCA1 associated protein 1 gene (BAP1)-deficient tumors, are currently being explored.
Introduction and Background
Malignant pleural mesothelioma (MPM) is a rare aggressive neoplasm that is closely linked to asbestos exposure. Median survival ranges between 6 and 8 months for patients treated with best supportive care and 12 and 16 months with pemetrexed-containing systemic cytotoxic therapy. 1 Therapy is generally palliative, improving symptoms and modestly increasing survival. 2, 3 Although asbestos control regulations have significantly decreased occupational exposure, many individuals remain at risk. 3, 4 Asbestos is the commercial name used to identify six different commercially used fibers; however, there are more than 400 asbestiform fibers in nature, and many, including erionite and antigorite, have been proved to be carcinogenic. 5 The Centers for Disease Control identified 45,221 MPM-related deaths in the United States between 1999 and 2015, with a 4.8% increase in MPM deaths over that period that was seen across all ethnicities. 4 Furthermore, Eastern Europe and other rapidly industrializing regions, where asbestos production and commercial use continues unregulated, may experience an increased incidence of MPM in coming decades. [6] [7] [8] Fewer MPM cases have been reported from East and Southeast Asia. It is hypothesized that this is secondary to a more recent industrialization and that numbers in these regions will start to rise in years to come. 9, 10 The ongoing increase in mortality related to MPM underscores the urgent need for asbestos control, improved understanding of the disease pathogenesis, early detection, and better treatment options.
Research output in this field has been increasing steadily. A comprehensive MEDLINE literature search identified relevant publications in 2017. On the basis of the expert opinion of the authors of this review, we elected and reviewed all publications relevant to the epidemiology, pathology, genomics, diagnosis, staging, and treatment of MPM that were published in 2017. In addition, we reviewed and included relevant abstracts of ongoing or recently completed MPM clinical trials presented at the 2017 Annual Meeting of the American Society of Clinical Oncology, 2017 European Society for Medical Oncology Congress, and the 2017 World Congress of Lung Cancer.
Lessons in Epidemiology and Occupational Medicine
Intraindividual biopersistence of asbestos fibers over time was analyzed in 12 longitudinally collected human lung tissue samples. The results suggested that the purportedly less carcinogenic chrysotile asbestos fibers also demonstrate a long biopersistence and therefore likely account for a proportion of MPM cases, 11 confirming suggestions by preclinical studies. 12 A second large study provided insights into the dose-time-response relationship between occupational asbestos exposure and pleural mesothelioma, suggesting that initial high doses of asbestos followed by low doses thereafter are associated with the highest risk. 13 Moreover, nonoccupational asbestos exposure is an increasingly recognized risk factor for MPM. In this context, a recent review and metaanalysis supported the critical need to evaluate MPM risk in communities with ambient asbestos or other carcinogenic fiber exposure.
14 Finally, in a large study across 230 countries over a 20-year period, the global burden of MPM deaths was extrapolated to about 38,400 per year, suggesting that the number might be even higher than the most recently reported values. 15 
Developments in Diagnosis and Staging
Blood-based biomarkers serve several potential roles in MPM: diagnostic, prognostic, or predictive of response to specific therapies. The most-studied blood-based biomarkers are mesothelin, osteopontin, fibulin-3, 16 and high mobility group box 1. 17 In 2017, three metaanalyses respectively confirmed that pretreatment thrombocytosis, 18 increased neutrophil-to-lymphocyte ratio, 19 and high serum levels of soluble mesothelin 20 are prognostic for poor survival. A recent study identified complement component 4d as a promising biomarker correlating with tumor volume, response to chemotherapy, and survival. 21 Other potentially useful blood-based diagnostic markers for mesothelioma include midkine, calretinin, and microRNA (miRNA). [22] [23] [24] [25] Deregulated miRNA levels of Let-7c-5p and miR-151a-5p in tissue may also be prognostic in MPM. 26 In addition, proteomic analysis of the secretome, including exosomes from MPM, cells identified proteins that potentially enhance the growth and stress response and inhibit adaptive immunity. 27, 28 Clinical and pathological staging is important to determine disease prognosis and facilitate patient selection for multimodality therapy. The International Association for the Study of Lung Cancer Mesothelioma Staging Project for the eighth edition of the American Joint Committee on Cancer/Union for International Cancer Control staging manual updated TNM staging in MPM. [29] [30] [31] However, the project database still overrepresented surgically treated patients, and despite recent advances in cross-sectional anatomic and functional imaging and mediastinal lymph node sampling, clinical staging remains difficult. One challenge is the inability to distinguish tumor tissue from surrounding normal tissue for staging and follow-up by using standard anatomic cross-sectional imaging. Although the current version of the modified Response Evaluation Criteria in Solid Tumors guidelines for MPM is more applicable to mesothelioma than Response Evaluation Criteria in Solid Tumors 1.0 or 1.1, further researchbased optimization of response criteria for MPM is still required. Tumor volume is increasingly recognized as an anatomic, imaging-based prognostic factor; however, valid and reliable measurement of this parameter across sites and software platforms is difficult. 32 Attempts to create an automated volumetric assessment of tumor volume for treatment response and prognostication have been difficult on account of a lack of accuracy and reproducibility. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] The most promising results on the prognostic value of CT-based tumor volume were recently published from a multi-institutional group. 43, 44 de Perrot et al. published data suggesting that lower radiological tumor volume and smaller diaphragmatic tumor thickness predicted favorable outcomes in patients treated with neoadjuvant radiation followed by extrapleural pneumonectomy (EPP). 45, 46 In addition, a group from the United Kingdom also reported a promising random walk-based computer-aided algorithm for image segmentation. 47 
Progresses in Pathology
The histological diagnosis of MPM is relatively well established when performed by expert pathologists on the basis of positive markers of mesothelial lineage and negative markers of epithelial lineage. However, diagnostic uncertainty remains common, and continued efforts to improve the accuracy of diagnosis are needed. 6 One of the most challenging differential diagnoses remains the distinction between sarcomatoid MPM and sarcomatoid carcinoma of the lung. In this respect, mucin 4, cell surface associated may be a novel sensitive and specific immunohistochemical biomarker for sarcomatoid carcinoma of the lung. 48 Moreover, GATA binding protein 3 immunostaining may be useful to identify sarcomatoid and desmoplastic mesothelioma. 49, 50 Disabled homolog 2 (DAB2) and intelectin-1 were reported as new positive immunohistochemical markers for epithelioid mesothelioma. 51 Another challenging differentiation has been between MPM and reactive mesothelial hyperplasia. Although BRCA1 associated protein 1 (BAP1) immunohistochemistry and p16 fluorescence hybridization can effectively discriminate MPM from reactive mesothelial hyperplasia, methylthioadenosine phosphorylase loss may also be useful when identified in combination with BAP1 loss. 52 In addition, several studies have focused on the evaluation of biomarkers of immunological activation and infiltrating immune cells, in particular, programmed death ligand 1 (PD-L1). [53] [54] [55] [56] The "don't eat me" signal CD47 was also shown to be overexpressed in diffuse malignant mesothelioma and was suggested as a potential diagnostic and therapeutic target of MPM. 57 
Molecular Advances
Previous genomic analysis identified the loss of various tumor suppressor genes as the most common molecular event in MPM. Commonly inactivated tumor suppressor genes include cyclin-dependent kinase inhibitor 2A gene (CDKN2A), BRCA1 associated protein 1 gene (BAP1), neurofibromin 2 gene (NF2), and occasionally tumor protein p53 gene (TP53). These findings have been confirmed in a recent comprehensive genomic analysis (Fig 1) . 58 Enhanced understanding of MPM molecular aberrations has already informed the use of targeted therapies such as the focal adhesion kinase (FAK) inhibitor defactinib for tumors lacking NF2 (COMMAND study). Unfortunately, maintenance defactinib did not improve patient outcomes and the study was terminated early. A recent publication provides a comprehensive review of molecular advances in MPM. 59 The role of heredity in familial predisposition to MPM, even without occupational asbestos exposure, has finally been proved by the discovery of germline BAP1 mutations, 60 and supported by murine modeling. 61, 62 As a result, the tumor-predisposing BAP1 cancer syndrome 63 has been increasingly recognized and characterized. 49, 64 BAP1 is a deubiquitinating enzyme with several roles in regulating DNA repair and gene expression.
predisposing to mesothelioma and other cancers, BAP1 is the most frequent acquired (somatic) mutation in sporadic mesothelioma. 66, 67 In 2017, both pleural and peritoneal mesotheliomas were shown to have loss of BAP1 in more than 60% of cases, 68, 69 confirming previous findings. 66 Novel functions of BAP1 that likely contribute to its role in cancer in general, and in MPM in particular, have been identified. Specifically, BAP1 is a master regulator of calcium-induced apoptosis through regulation of the inositol 1,4,5-triphosphate receptor type 3 receptor ubiquitination, 70 as well as a regulator of cellular glycolytic metabolism 71 and a radical of oxygen homeostasis. 72 A novel alternative splice isoform of BAP1 that is missing part of the catalytic domain has also been described, and it appears to regulate DNA damage response and influence drug sensitivity. 73 Furthermore, frequent germline mutations in other genes associated with DNA repair have been identified in asbestosexposed individuals with development of MPM, suggesting that these pathways are associated with MPM predisposition. 74 Interestingly, common germline BAP1 variants appear to mediate the risk of development of renal cell carcinoma and lung cancer, 75 and possibly also MPM. 76 When mesothelioma develops in carriers of germline BAP1 mutations, these malignancies have a much better prognosis, and survival of 5 or more years is commonly seen. 77 In 2017, the role of BAP1 immunohistochemistry in MPM diagnosis and possibly prognosis was also the focus of several studies. Specifically, BAP1 loss was shown to reliably differentiate MPM from chronic pleuritis, benign mesothelial hyperplasia, and other benign mesothelial lesions, as well as from other malignancies such as NSCLC and ovarian serous tumors. 52, [78] [79] [80] [81] [82] The identification of hereditary factors in MPM pathogenesis has also led to increased interest in the characterization of young patients. In 2017 it was reported that these patients show distinctive clinical, pathological, and genetic features, such as higher ARF expression increases MDM2 levels and decreases p53 function, resulting in increased cell survival. p16
INK4a is essential in hyperphosphorylation and subsequent inhibition of the retinoblastoma pathway. Loss of this cyclin-dependent kinase inhibitor leads to unchecked activation of the retinoblastoma pathway and, ultimately, to cell cycle progression. Tumor protein p53 gene (TP53) encodes p53, and loss of this gene results in loss of p53 and subsequent cell proliferation and survival.
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likelihood of a history of mantle radiation, family history of breast cancer, and lower rates of CDKN2A deletion than in older patients. 83 Moreover, a subset of mesotheliomas in young patients (15%) were associated with recurrent EWS RNA binding protein 1 gene (EWSR1)/ FUS RNA binding protein gene (FUS)-ADP ribosylation factor 1 gene (ATF1) fusions. 84 Most importantly, the presence of clinically actionable ALK receptor tyrosine kinase gene (ALK) rearrangements was described in about 10% of peritoneal mesothelioma, most commonly in younger women. 85 
Systemic Therapies

Targeting Angiogenesis
Systemic cytotoxic chemotherapy with pemetrexed plus cisplatin remains the only U.S Food and Drug Administration-approved therapy for MPM and represents the current standard of care. With treatment response rates of approximately 40%, it extends median overall survival (OS) to 12 to 16 months. 86 As vascular endothelial growth factor (VEGF) signaling is important in the pathophysiology of MPM, VEGF inhibition is being explored as a potential treatment option. [87] [88] [89] [90] The results of the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS) demonstrated a statistically significant improvement in OS when bevacizumab was added to first-line cisplatin and pemetrexed chemotherapy. 91 However, because of the observed relatively small increase in OS, the addition of bevacizumab to chemotherapy has not become the standard of care in most parts of the world, and it is recommended as optional in the National Comprehensive Cancer Network guidelines. 91 A cost-effectiveness analysis published in 2017 did not support the addition of bevacizumab. 92 Another antiangiogenic, nintedanib, is a small molecule tyrosine kinase inhibitor targeting VEGF receptors, fibroblast growth factor receptors, and platelet-derived growth factor receptors. The LUME-MESO study is an ongoing randomized, double-blind, placebo-controlled phase II/III trial examining the efficacy and safety of adding nintedanib to standard chemotherapy in patients non-surgically treated MPM; phase II results were reported in 2017. 93 In 87 evaluable patients (44 receiving nintedanib and 43 receiving placebo), nintedanib improved progression-free survival (PFS) by 3.7 months as compared with placebo (p ¼ 0.01), most notably in those with epithelioid histological features (4 months PFS [p ¼ 0.006]). There was a trend toward improved OS (median 18.3 months versus 14.2 months) in favor of the nintedanib group; however, this difference was not statistically significant and the study was not powered to examine OS. The addition of nintedanib to standard chemotherapy was safe, and these results support the rationale for the ongoing phase III study (Table 1) . [93] [94] [95] [96] [97] Blocking Immune Checkpoints
In 2017 immunotherapy was clearly the focus of the largest number of clinical trials investigating new therapies for MPM. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) is expressed on T cells, reducing the amplitude of CD28-mediated T-cell activation.
98 CTLA4 inhibition enhances T-cell activation and increases antitumor efficacy in other cancers. 99 Phase II studies investigating tremelimumab, a selective human monoclonal antibody against CTLA4, showed favorable PFS responses and toxicity profiles. 100, 101 In 2017, the double-blind study comparing tremelimumab to placebo in subjects with previously treated unresectable malignant mesothelioma (DETERMINE) disappointingly failed to demonstrate differences in OS or PFS between the treatment and control groups ( Table 2) . [102] [103] [104] [105] [106] [107] [108] [109] [110] Characterization of the immunological tumor microenvironment has been the subject of considerable research, and the immune status of MPM has been distinctly correlated to prognosis. 111, 112 Approximately 60% of MPM either expressed PD-L1 or displayed an "inflamed status" designated by a specific mRNA signature, indicating potential susceptibility to immune-directed therapy. 113, 114 Human monoclonal antibodies against programmed cell death protein 1 (PD-1) and PD-L1 are approved for multiple malignancies, including first-line therapy for NSCLC alone for tumors with 50% or more PD-L1 staining 115, 116 or in combination with chemotherapy regardless of PD-L1 staining for adenocarcinoma. 117 There are many ongoing clinical trials investigating PD-1/PD-L1 checkpoint inhibitors alone and in combination.
Single-Agent Immunotherapy Trials. Between 20% and 40% of patients with MPM express PD-L1 at various levels, and PD-L1 expression correlates with a poorer prognosis. 113, 118 In the KEYNOTE-028 trial, the efficacy and safety of pembrolizumab as subsequent-line therapy was evaluated in 25 patients with PD-L1-positive MPM (1% PD-L1 positivity). 106 Twenty percent of patients achieved a partial response and 52% demonstrated stable disease, with a 12-month median duration of response. Furthermore, the median PFS (5.4 months) and the median OS (18 months) were notably longer than in patients not receiving second-line therapy. PD-L1 positivity and level of expression were not clearly linked to likelihood of clinical response. 106 The Netherlands Cancer Institute is currently conducting a similar phase II trial of a PD-1 inhibitor, nivolumab, in patients with relapsed MPM. Preliminary results reported a disease control rate of 50% at 12 weeks and 33% at 24 weeks, with a median PFS of 3.6 months. 104 Avelumab, an anti-PD-L1 antibody, also demonstrated clinical activity against MPM in the JAVELIN study, with a response rate of 9.4%, stability in 47% of patients, and median PFS of 4.3 months. 103 Similar results have been reported from a phase II trial of pembrolizumab 107 and the nivolumab MERIT study. 105 The ongoing phase III CONFIRM study randomizes patients requiring second-line therapy to nivolumab or placebo (NCT03063450). The PROMISE-Meso study, which is comparing pembrolizumab to gemcitabine or vinorelbine in patients with pretreated, non-surgically treated MPM, is also currently recruiting (NCT02991482).
Immunotherapy Combination Trials. In 2017, preliminary findings of several ongoing studies investigating combination immune checkpoint inhibition pairing anti-PD-1/PD-L1 therapy with anti-CTLA4 therapy were also reported. Preliminary results of the NIBIT-MESO (tremelimumab and durvalumab), 109 MAPS-2, 108 and INITIATE (both ipilimumab and nivolumab) 110 trials demonstrated potential efficacy for second-line therapy for mesothelioma. MAPS-2 is a phase II study including 108 evaluable patients treated with nivolumab versus nivolumab plus ipilimumab. Although the results in the nivolumab arm were promising, the 54 patients in the combination arm had a higher durable controlled response rate (51.6%), although three treatment-related deaths were also reported. 108 Sixty percent of patients in the NIBIT-MESO trial experienced adverse events, with three patients requiring study discontinuation on account of treatment-related toxicity. 109 INITIATE appears to be the most favorable thus far on the basis of preliminary data from a 12-week analysis, with a durable controlled response rate of 72% and only 29% of patients experiencing grade 3 or 4 toxicity. 110 Checkmate 743 is an ongoing randomized controlled phase III study comparing the combination of ipilimumab and nivolumab with pemetrexed/cisplatin as first-line therapy in 600 patients; it is approaching completion of enrolment. 119 Further studies are addressing combinations of anti-PD-1/PD-L1 therapy with chemotherapy. The DREAM study is evaluating the effect of durvalumab (anti-PD-L1) plus standard chemotherapy followed by durvalumab alone; it has completed recruitment. 120 (Table 3) .
On the basis of recent evidence suggesting a role for focal adhesion kinase in regulation of the immunosuppressive microenvironment 121 and synergy between FAK and PD-1 inhibition, 122 a proof of concept phase 1b/2A clinical trial of pembrolizumab and FAK is ongoing and includes a mesothelioma cohort (NCT02758587).
Although PD-1/PD-L1-targeted checkpoint inhibition has demonstrated promising clinical responses in early-phase studies, the results of the ongoing phase III studies described are needed to better define the role of this approach. It is unclear whether the potentially small additional benefit of combination immune checkpoint inhibition will justify the increased toxicity.
Promising Targeted Therapies
BAP1 Loss in MPM. BAP1 plays an independent role in epigenetic regulation and malignant transformation. BAP1 loss results increased trimethylated histone H3 lysine 27 (H3K27me3), increased enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) expression, and enhanced repression of polycomb repressive complex 2 (PRC2) targets. In preclinical models EZH2 inhibition has been shown to be beneficial in MPM with BAP1 loss 123 (see Fig. 1 ). A phase II clinical trial investigating the EZH2 inhibitor tazemetostat in MPM completed enrollment, and results should be available soon (NCT02860286). BAP1 inactivation alters double-strand DNA repair through homologous recombination. 71, 124 However, the potential implications for poly(ADP ribose) polymerase (PARP) inhibitor sensitivity in mesothelioma have not yet been evaluated, although the MiST 1 study is currently in development in the United Kingdom.
Targeting Mesothelin. Mesothelin is a cell surface glycoprotein expressed on cells lining the pleura, peritoneum, and pericardium, as well as on MPM cancer cells. 125, 126 It is an attractive potential target in MPM owing to its high surface expression 127, 128 and its suspected involvement in tumorigenesis. 129 Mesothelintargeted therapies involving antimesothelin immunotoxins (SSP1), chimeric antimesothelin antibodies (amatuximab), mesothelin-directed antibodydrug conjugates (anetumab ravtansine), Listeria-based vaccines (CRS-207), and chimeric antigen receptor expressing T-cells (CAR-T-cells) have shown some promise in early-phase studies 130 ( Fig. 2) , and further studies are ongoing. The recently reported randomized, open-label, active-controlled, multicenter superiority phase II study investigating anetumab ravtansine versus vinorelbine as second-line treatment in patients with mesothelin-positive MPM (248 patients) did not show a difference between the treatment groups 95 (see Table 1 ). However, there are additional promising preclinical models. Recently, a preclinical study combining direct tumor injection of mesothelin immunotoxin with intraperitoneal injection of anti-CTLA4 therapy demonstrated an 86% complete response (CR) rate in directly treated tumors and a 56% CR of a second untreated tumor, whereas no CR occurred when both drugs were given separately. 131 A similar combination approach using an antimesothelin immunotoxin (RG7787) plus nab-paclitaxel (albuminbound paclitaxel) in mesothelioma cell lines was also published. Three of four lines revealed durable CR, and studies in human patients began in 2017. 132 Arginine Deprivation Therapy. Argininosuccinate synthetase 1 (ASS1) is the rate-limiting enzyme in arginine production, and cell lines deficient in ASS1 usually require exogenous arginine supplementation 133 (Fig. 3) . Intratumoral ASS1 deficiency has been identified in 63% of archived mesothelioma lines and is associated with increased tumorigenesis and more aggressive disease. [133] [134] [135] In vitro studies of arginine deprivation with adenosine deaminase (ADI-PEG20) show improved PFS with low toxicity. [136] [137] [138] [139] [140] Szlosarek et al. applied this concept to mesothelioma, conducting the first prospective biomarker-driven randomized controlled trial in this disease. 96 A total of 41 patients received ADI-PEG20 plus best supportive care and 24 patients received best supportive care only, with predetermined interval imaging to assess for progression of disease. They observed a median PFS of 3.2 months in the treatment group as compared with 2.0 months in the control group (p ¼ 0.03) 96 (see Table 2 ). These findings led to a phase I study of ADI-PEG20 combined with standard-of-care chemotherapy in patients with ASS1-deficient mesothelioma and NSCLC. 97 Nine patients (five with MPM) received escalating weekly doses of ADI-PEG20 with standard chemotherapy. No dose-limiting toxicities were encountered, and only nine reported adverse events (most commonly rash) were related to ADI-PEG20. All patients experienced stable disease, and seven (78%) achieved a partial response, including one with sarcomatoid MPM. These results suggested that coadministration of standard chemotherapy and arginine deprivation therapy in ASS1-negative patients was well tolerated and could improve tumor response over chemotherapy alone. 97 A phase II/III trial is currently recruiting patients with MPM with 75% loss of ASS1. 141 Figure 2. Potential therapeutic targets of mesothelin surface proteins. This figure demonstrates the proposed mechanisms of mesothelioma treatment specifically targeting mesothelin, including through monoclonal antibodies, immunotoxins, antibodydrug conjugates, virus-packed vaccine therapy, and chimeric antigen receptor (CAR) T-cell therapy. APC, antigen presenting cell; CRS207, attenuated strain of Listeria engineered to express mesothelin; DM4, tubulin inhibitor; PE38, pseudomonas exotoxin A-38; SS1P, mesothelin-binding antibody; TCR, T-cell receptor; MHC, major histocompatibility complex.
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Progress in MPM in 2017NF2-Targeted Therapies. NF2 is a gene that is commonly inactivated in MPM. This gene encodes Merlin, which regulates the Hippo tumor suppressive signaling pathway. Hippo pathway dysregulation leads to constitutive activation of YY1 associated protein 1/tafazzin transcriptional coactivators and enhances malignant phenotypes of malignant mesothelioma cells. 142 Although the progress of MPM research based on NF2 alteration was limited in 2017, novel therapeutic strategies against YY1 associated protein 1/ tafazzin have been developed for a variety of human malignancies, including MPM. 143 Merlin can also accumulate in the nucleus and suppresses tumorigenesis by inhibiting the cullin E3 ubiquitin ligase CRL4 DCAF1 . Combining an NEDD8-activating enzyme inhibitor, which suppresses CRL4 DCAF1 , and mammalian target of rapamycin/phosphoinositide 3-kinase inhibitor suppresses the growth of in NF2-mutant mesothelioma and schwannoma cells. 144 Other Potential Systemic Therapies. Promising results in the adjuvant setting using the WT-1 peptide vaccine galinpepimut-S after multimodality therapy were shown in a randomized phase II trial, but the trial lacked statistical power to draw stronger conclusions. 145 Autologous monocyte-derived dendritic cell immunotherapy pulsed with allogenic tumor cell line lysate was effective in mice and safe in nine patients with MPM in a phase I trial. 146 A novel therapeutic strategy currently at a preclinical stage for MPM is the inhibition of the protumor alarmin high mobility group box 1 by a number of compounds such as ethyl pyruvate 147 and aspirin. 148 The antitumoral properties of various viruses have been demonstrated in a number of malignancies. [149] [150] [151] [152] [153] MPM has been the target of many such investigations, 154 and promising preclinical data regarding adenovirus oncotherapy [155] [156] [157] [158] prompted human studies. Herpes simplex virus-1 oncotherapy has shown dramatic responses in vitro, [159] [160] [161] and preliminary results in human patients revealed a 50% disease stability rate. 162 In murine xenografted models of mesothelioma, intrapleural oncolytic vaccinia virus administration resulted in improved 30-day survival. 163 There have also been several promising studies of MPM and intrapleural administration of oncolytic measles viruses, 164, 165 and a phase I study to evaluate efficacy in humans is ongoing. 166 Other promising therapeutic candidates include the monopolar spindle 1 kinase, a kinase of the spindle assembly checkpoint that controls cell division and cell fate 167 ; the mammalian target of rapamycin/phosphoinositide 3-kinase/AKT axis for the aggressive subset of MPM harboring simultaneous inactivating mutations of the genes LATS2 and NF2
168 ; the sialylated protein heart development protein with EGF like domains 1, which can be targeted by a specific monoclonal antibody 169 ; and targeting of v-myc avian myelocytomatosis viral oncogene homolog MYC, which is up-regulated in MPM cells. 170 The first-in-human phase I trial of anti-CD26 antibody, YS110, was also conducted with 33 patients, including 22 with MPM. 171 Several mRNAs have been reported as potential therapeutic targets with proof of concept in clinical trials (e.g., the miRNA-15/16 family, 172, 173 or miRNA-137, through its control of YB-1). 174 Interestingly, miRNAs have been shown to contribute to the regulation of PD-L1 expression, 175 opening to novel potential combinations between miRNA-targeting drugs and immune checkpoint inhibitors.
To further bridge preclinical and clinical results, the availability of relevant in vitro and in vivo models is crucial. In this respect, the establishment of primary MPM culture systems to test novel drugs 176, 177 and patientderived xenografts from pleural mesothelioma 178 represented a significant scientific advance in 2017.
Surgical Resection
Optimal treatment of MPM remains controversial, particularly the role of localized therapies such as surgery and radiation. Historically, operable patients underwent EPP, which has significant complications and substantial mortality with no appreciable benefit to the patient demonstrated by the small randomized MARS pilot study. 179 Pleurectomy/decortication (P/D) was then introduced in an attempt to offer a lung-sparing macroscopic resection of the tumor. Previous uncontrolled studies have suggested that this procedure is associated with fewer adverse events, with equivalent to improved survival benefits. [180] [181] [182] [183] [184] [185] [186] Despite these findings, clinical equipoise regarding the true benefit of either operation remains. In 2017, two large observational studies using the National Cancer Database were conducted. In the first, propensity score matching analysis showed that surgery-based multimodality therapy was associated with improved survival and may offer therapeutic benefit among carefully selected patients. 187 A second study evaluated 271 patients who underwent EPP and 1036 patients who received P/D. They found no statistically significant differences in OS (19 months To further complicate the debate, a relatively large retrospective multicenter study suggested that extended P/D or nonextended P/D (i.e., P/D without resection of the diaphragm and/or pericardium) had similar outcomes in terms of early results and survival rate. 189 A recently published comprehensive review on quality of life in MPM showed that quality of life was generally better for patients undergoing P/D than for those undergoing EPP. 190 Presently, the ongoing MARS2 trial is comparing P/D versus no surgery; in 2017 the study surpassed its futility end point and patient enrollment will continue. 191 
Advances in RT
The ostensible goal of surgery in MPM has been macroscopic complete resection. Surgical resection alone is associated with frequent locoregional recurrences, 185, 192 suggesting that adjuvant or neoadjuvant radiotherapy (RT) in a multimodality approach may have a role in improving recurrence control. However, the role of RT after EPP has been questioned on the basis of a recently published randomized controlled study. 193 A systematic review assessing the role of RT after lung-sparing surgery (P/D) in MPM 194 concluded that RT can be delivered safely, with encouraging survival data and acceptable levels of toxicity after a lung-sparing procedure in MPM. Memorial Sloan-Kettering Cancer Center has been at the forefront of research regarding intensity-modulated radiation therapy (IMRT) after P/D, with studies demonstrating encouraging OS without a significant increase in radiation pneumonitis. [195] [196] [197] Shaikh et al. evaluated the effect of hemithoracic IMRT compared with conventional RT in patients treated with P/D. 198 The study analyzed 209 patients (131 undergoing conventional RT and 78 undergoing IMRT) and demonstrated a statistically improved OS in the IMRT arm (median 20.2 versus 12.3 months [p ¼ 0.001]). Notably, patients in this arm were also more likely to have achieved a macroscopically complete resection (p ¼ 0.01), epithelioid histological features (p ¼ 0.003), and higher Karnofsky performance scores upon initial receipt of RT (p ¼ 0.01), and they were less likely to experience esophagitis (p ¼ 0.0007) according to multivariable analysis. There were no significant differences in rates of local recurrence. 198 Another promising approach has been neoadjuvant high-dose RT to the ipsilateral lung followed by EPP. Pioneered by the Toronto group led by Drs. de Perrot and Cho, this approach has been shown to be safe and has demonstrated a very favorable OS. 199, 200 This group treated 90 patients between November 2008 and February 2017, with a median survival of 28.3 months for the intention-to-treat population. This approach may be most beneficial in patients with epithelial tumors, low tumor volume, and no lymph node metastasis. 45, 193 Of note, carriers of germline BAP1 mutations may have a high risk for development of a second malignancy when treated with RT. Therefore, RT should be used with caution, which is similar to the treatment guidelines for patients with Li-Fraumeni syndrome.
Advances in Palliative Care
In contrast to lung cancer, a recently reported randomized study did not demonstrate any benefit of early implementation of palliative care for MPM (RESPECT-Meso Study). 201 It is worth noting that the RESPECT study was conducted in the United Kingdom and Australia by centers with significant nursing support for patients and its conclusions do not necessarily negate the potential benefit of palliative care in other health care settings. In addition, the recently presented PIT Study demonstrated that prophylactic intervention track site radiation did not prevent the occurrence and symptoms of tract site metastasis. The frequency of tract site metastasis was not significantly different: 3.2% in the RT group and 5.3% in the control group. 202 Furthermore, recent data demonstrated that the use of an indwelling pleural catheter resulted in fewer hospital days and fewer subsequent interventions than talc slurry pleurodesis in a randomized study of 144 patients (approximately 25% of patients in each group had MPM). 203 It is important to note, however, that clinical concern remains for seeding along a chest tube tract in patients with MPM. 204 
Conclusion
The year 2017 was characterized by several important advances in this field, although only a minority would be considered practice changing. As of today, pemetrexed-based cytotoxic chemotherapy with or without bevacizumab remains the standard of care for most patients. Immunotherapy trials remain an exciting area of investigation, though whether the benefits of combination anti-CTLA4 and anti-PD-1/PD-L1 immunotherapy will outweigh the increased risk of toxicity remains unclear. Many single-agent and combination immunotherapy trials are ongoing, and additional results are expected for 2018-2019. Although physiciandirected immune checkpoint inhibitor therapy has now been included in the current National Comprehensive Cancer Network guidelines as an option for second-line therapy for MPM, the efficiency of this approach remains unproved, and as such these patients should primarily be encouraged to enroll in ongoing clinical trials.
Improved understanding of MPM molecular biology and the immunological tumor microenvironment provide future therapeutic applications, most notably through the BAP1 pathway.
Although the role of multimodality therapy including surgery remains controversial, it is encouraging that there are several new approaches and ongoing multicenter studies. The MARS-2 study surpassed its futility end point and preliminary findings are expected in the upcoming years. The 2017 advances will, it is hoped, be followed by significant clinical translation and result in the urgently needed improved therapeutic strategies for this devastating disease.
